Companion diagnostics

David Rimm continues the conversation about the best assay for atezolizumab after a recent response to his original article

Emina Torlakovic and Allen Gown share their disagreements with David Rimm’s comments about an FDA-approved PD-L1 assay for atezolizumab

Not every assay that trials well is practical for implementation in daily practice. How can we tell which ones are, and whose responsibility is it?

A response to David Rimm’s letter that supports the role of PD-L1 testing in improving outcomes for cancer patients.

David Rimm challenges the sensitivity and reproducibility of a new assay for PD-L1 detection.

Liquid biopsy can help us appropriately treat patients with anti-PD-L1 immunotherapies, and ddPCR enables ongoing monitoring and adjustment of treatment

An efficient alternative to pap-HPV tests could lie with ddPCR and a ccfDNA assay

New collaborative guidelines for molecular biomarker testing in colorectal cancer

An examination of domain-specific companion diagnostic testing

An industry pathologist’s perspective on developing a companion diagnostic